GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BTG PLC (OTCPK:BTGGF) » Definitions » Debt-to-EBITDA

BTG (BTGGF) Debt-to-EBITDA : 0.00 (As of Mar. 2019)


View and export this data going back to . Start your Free Trial

What is BTG Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BTG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2019 was $0.0 Mil. BTG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2019 was $0.0 Mil. BTG's annualized EBITDA for the quarter that ended in Mar. 2019 was $180.6 Mil. BTG's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2019 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BTG's Debt-to-EBITDA or its related term are showing as below:

BTGGF's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Debt-to-EBITDA only.

BTG Debt-to-EBITDA Historical Data

The historical data trend for BTG's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BTG Debt-to-EBITDA Chart

BTG Annual Data
Trend Mar10 Mar11 Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BTG Semi-Annual Data
Sep09 Mar10 Sep10 Mar11 Sep11 Mar12 Sep12 Mar13 Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BTG's Debt-to-EBITDA

For the Biotechnology subindustry, BTG's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BTG's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BTG's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BTG's Debt-to-EBITDA falls into.



BTG Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BTG's Debt-to-EBITDA for the fiscal year that ended in Mar. 2019 is calculated as

BTG's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2019 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Mar. 2019) EBITDA data.


BTG  (OTCPK:BTGGF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BTG Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BTG's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BTG (BTGGF) Business Description

Traded in Other Exchanges
N/A
Address
5 Fleet Place, London, GBR, EC4M 7RD
BTG is a biotechnology company that develops products in specialty areas of medicine. The company's three operating segments are interventional medicine, specialty pharmaceuticals, and licensing. Its interventional medicine focuses on oncology, vascular treatments, and pulmonology. BTG's revenue is roughly split between these three segments, while its oncology operations lead the interventional segment. The company has been known to utilize acquisitions for investing in leading therapies and capabilities.